共 110 条
[1]
Stratton IM(2000)Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 405-412
[2]
Adler AI(2009)Diabetes mellitus in the Netherlands: estimate of the current disease burden and prognosis for 2025 Ned Tijdschr Geneeskd 153 1052-1058
[3]
Neil HA(2013)The NHG guideline diabetes mellitus type 2 Huisarts Wet 56 512-525
[4]
Baan CA(2012)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 1364-1379
[5]
van Baal PH(2006)Insulin treatment and the problem of weight gain in type 2 diabetes Diabetes Educ 32 910-917
[6]
Jacobs-van der Bruggen MA(2005)Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study Diabetes Care 28 2673-2679
[7]
Rutten GEHM(2007)Intensification of therapy and no increase in body mass index with longer disease duration in type 2 diabetes mellitus (ZODIAC-5) Fam Pract 24 529-531
[8]
De Grauw WJC(2009)Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 85 520-526
[9]
Nijpels G(2012)Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 156 405-415
[10]
Inzucchi SE(2006)Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) Curr Med Res Opin 22 121-129